279 related articles for article (PubMed ID: 28008921)
21. Activation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors: suggestion of combination therapy.
Torka R; Pénzes K; Gusenbauer S; Baumann C; Szabadkai I; Őrfi L; Kéri G; Ullrich A
Neoplasia; 2014 Apr; 16(4):301-18. PubMed ID: 24862757
[TBL] [Abstract][Full Text] [Related]
22. AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers.
Balaji K; Vijayaraghavan S; Diao L; Tong P; Fan Y; Carey JP; Bui TN; Warner S; Heymach JV; Hunt KK; Wang J; Byers LA; Keyomarsi K
Mol Cancer Res; 2017 Jan; 15(1):45-58. PubMed ID: 27671334
[TBL] [Abstract][Full Text] [Related]
23. Axl/Gas6/NFκB signalling in schwannoma pathological proliferation, adhesion and survival.
Ammoun S; Provenzano L; Zhou L; Barczyk M; Evans K; Hilton DA; Hafizi S; Hanemann CO
Oncogene; 2014 Jan; 33(3):336-46. PubMed ID: 23318455
[TBL] [Abstract][Full Text] [Related]
24. Regulation of the Receptor Tyrosine Kinase AXL in Response to Therapy and Its Role in Therapy Resistance in Glioblastoma.
Scherschinski L; Prem M; Kremenetskaia I; Tinhofer I; Vajkoczy P; Karbe AG; Onken JS
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35055167
[TBL] [Abstract][Full Text] [Related]
25. PI3Kγδ inhibitor plus radiation enhances the antitumour immune effect of PD-1 blockade in syngenic murine breast cancer and humanised patient-derived xenograft model.
Han MG; Jang BS; Kang MH; Na D; Kim IA
Eur J Cancer; 2021 Nov; 157():450-463. PubMed ID: 34601286
[TBL] [Abstract][Full Text] [Related]
26. Role of the Receptor Tyrosine Kinase Axl and its Targeting in Cancer Cells.
Corno C; Gatti L; Lanzi C; Zaffaroni N; Colombo D; Perego P
Curr Med Chem; 2016; 23(15):1496-512. PubMed ID: 27048336
[TBL] [Abstract][Full Text] [Related]
27. Repression of AXL expression by AP-1/JNK blockage overcomes resistance to PI3Ka therapy.
Badarni M; Prasad M; Balaban N; Zorea J; Yegodayev KM; Joshua BZ; Dinur AB; Grénman R; Rotblat B; Cohen L; Elkabets M
JCI Insight; 2019 Mar; 5(8):. PubMed ID: 30860495
[TBL] [Abstract][Full Text] [Related]
28. Targeting Axl and Mer kinases in cancer.
Verma A; Warner SL; Vankayalapati H; Bearss DJ; Sharma S
Mol Cancer Ther; 2011 Oct; 10(10):1763-73. PubMed ID: 21933973
[TBL] [Abstract][Full Text] [Related]
29. Immunological role of TAM receptors in the cancer microenvironment.
Gadiyar V; Patel G; Davra V
Int Rev Cell Mol Biol; 2020; 357():57-79. PubMed ID: 33234245
[TBL] [Abstract][Full Text] [Related]
30. Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer.
Sen T; Tong P; Diao L; Li L; Fan Y; Hoff J; Heymach JV; Wang J; Byers LA
Clin Cancer Res; 2017 Oct; 23(20):6239-6253. PubMed ID: 28698200
[No Abstract] [Full Text] [Related]
31. Axl and Mer Receptor Tyrosine Kinases: Distinct and Nonoverlapping Roles in Inflammation and Cancer?
Dransfield I; Farnworth S
Adv Exp Med Biol; 2016; 930():113-32. PubMed ID: 27558819
[TBL] [Abstract][Full Text] [Related]
32. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma.
Zhou L; Liu XD; Sun M; Zhang X; German P; Bai S; Ding Z; Tannir N; Wood CG; Matin SF; Karam JA; Tamboli P; Sircar K; Rao P; Rankin EB; Laird DA; Hoang AG; Walker CL; Giaccia AJ; Jonasch E
Oncogene; 2016 May; 35(21):2687-97. PubMed ID: 26364599
[TBL] [Abstract][Full Text] [Related]
33. AXL Inhibitor TP-0903 Reduces Metastasis and Therapy Resistance in Pancreatic Cancer.
Zhang Y; Arner EN; Rizvi A; Toombs JE; Huang H; Warner SL; Foulks JM; Brekken RA
Mol Cancer Ther; 2022 Jan; 21(1):38-47. PubMed ID: 34675118
[TBL] [Abstract][Full Text] [Related]
34. Implication of the Receptor Tyrosine Kinase AXL in Head and Neck Cancer Progression.
von Mässenhausen A; Brägelmann J; Billig H; Thewes B; Queisser A; Vogel W; Kristiansen G; Schröck A; Bootz F; Brossart P; Kirfel J; Perner S
Int J Mol Sci; 2016 Dec; 18(1):. PubMed ID: 28025482
[TBL] [Abstract][Full Text] [Related]
35. Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET.
Rankin EB; Fuh KC; Castellini L; Viswanathan K; Finger EC; Diep AN; LaGory EL; Kariolis MS; Chan A; Lindgren D; Axelson H; Miao YR; Krieg AJ; Giaccia AJ
Proc Natl Acad Sci U S A; 2014 Sep; 111(37):13373-8. PubMed ID: 25187556
[TBL] [Abstract][Full Text] [Related]
36. AXL kinase-mediated astrocytic phagocytosis modulates outcomes of traumatic brain injury.
Zhou H; Hu L; Li J; Ruan W; Cao Y; Zhuang J; Xu H; Peng Y; Zhang Z; Xu C; Yu Q; Li Y; Dou Z; Hu J; Wu X; Yu X; Gu C; Cao S; Yan F; Chen G
J Neuroinflammation; 2021 Jul; 18(1):154. PubMed ID: 34233703
[TBL] [Abstract][Full Text] [Related]
37. A critical role of Gas6/Axl signal in allergic airway responses during RSV vaccine-enhanced disease.
Shibata T; Ato M
Immunol Cell Biol; 2017 Nov; 95(10):906-915. PubMed ID: 28722020
[TBL] [Abstract][Full Text] [Related]
38. Acquired resistance to EGFR tyrosine kinase inhibitors is mediated by the reactivation of STC2/JUN/AXL signaling in lung cancer.
Liu YN; Tsai MF; Wu SG; Chang TH; Tsai TH; Gow CH; Chang YL; Shih JY
Int J Cancer; 2019 Sep; 145(6):1609-1624. PubMed ID: 31162839
[TBL] [Abstract][Full Text] [Related]
39. Targeting the degradation of AXL receptor tyrosine kinase to overcome resistance in gefitinib-resistant non-small cell lung cancer.
Bae SY; Hong JY; Lee HJ; Park HJ; Lee SK
Oncotarget; 2015 Apr; 6(12):10146-60. PubMed ID: 25760142
[TBL] [Abstract][Full Text] [Related]
40. Axl signaling induces development of natural killer cells in vitro and in vivo.
Kim EM; Lee EH; Lee HY; Choi HR; Ji KY; Kim SM; Kim KD; Kang HS
Protoplasma; 2017 Mar; 254(2):1091-1101. PubMed ID: 27549806
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]